» Articles » PMID: 24607936

Symptomatic Reflux Disease: the Present, the Past and the Future

Overview
Journal Gut
Specialty Gastroenterology
Date 2014 Mar 11
PMID 24607936
Citations 89
Authors
Affiliations
Soon will be listed here.
Abstract

The worldwide incidence of GORD and its complications is increasing along with the exponentially increasing problem of obesity. Of particular concern is the relationship between central adiposity and GORD complications, including oesophageal adenocarcinoma. Driven by progressive insight into the epidemiology and pathophysiology of GORD, the earlier belief that increased gastroesophageal reflux mainly results from one dominant mechanism has been replaced by acceptance that GORD is multifactorial. Instigating factors, such as obesity, age, genetics, pregnancy and trauma may all contribute to mechanical impairment of the oesophagogastric junction resulting in pathological reflux and accompanying syndromes. Progression of the disease by exacerbating and perpetuating factors such as obesity, neuromuscular dysfunction and oesophageal fibrosis ultimately lead to development of an overt hiatal hernia. The latter is now accepted as a central player, impacting on most mechanisms underlying gastroesophageal reflux (low sphincter pressure, transient lower oesophageal sphincter relaxation, oesophageal clearance and acid pocket position), explaining its association with more severe disease and mucosal damage. Since the introduction of proton pump inhibitors (PPI), clinical management of GORD has markedly changed, shifting the therapeutic challenge from mucosal healing to reduction of PPI-resistant symptoms. In parallel, it became clear that reflux symptoms may result from weakly acidic or non-acid reflux, insight that has triggered the search for new compounds or minimally invasive procedures to reduce all types of reflux. In summary, our view on GORD has evolved enormously compared to that of the past, and without doubt will impact on how to deal with GORD in the future.

Citing Articles

Cyanidin and Cyanidin-3-Glucoside Alleviate Peptic Ulcer Disease: Insights from in vitro, and in vivo Studies.

Prayoga D, Aulifa D, Budiman A, Levita J, Jiranusornkul S Drug Des Devel Ther. 2025; 19:841-856.

PMID: 39935574 PMC: 11812437. DOI: 10.2147/DDDT.S500645.


Assessment of upper respiratory and gut bacterial microbiomes during COVID-19 infection in adults: potential aerodigestive transmission.

Al-Momani H, Nelson A, Al Balawi H, Al Balawi D, Aolymat I, Khasawneh A Sci Rep. 2025; 15(1):1811.

PMID: 39805887 PMC: 11730684. DOI: 10.1038/s41598-025-85806-5.


Impact of Metabolic Health and Its Changes on Erosive Esophagitis Remission: A Cohort Study.

Kim N, Chang Y, Ryu S, Sohn C J Neurogastroenterol Motil. 2025; 31(1):54-62.

PMID: 39779204 PMC: 11735195. DOI: 10.5056/jnm24058.


Associations of Plant-Based Foods, Animal Products, and Selected Sociodemographic Factors with Gastroesophageal Reflux Disease Risk.

El Shikieri A, Eltahir Z, Aman A, Alhadramy M Int J Environ Res Public Health. 2025; 21(12.

PMID: 39767535 PMC: 11728439. DOI: 10.3390/ijerph21121696.


Established and Novel Methods to Assess GERD: An Update.

Schweckendiek D, Pohl D Visc Med. 2024; 40(6):331-338.

PMID: 39664095 PMC: 11631016. DOI: 10.1159/000540186.


References
1.
Jacobson B, Somers S, Fuchs C, Kelly C, Camargo Jr C . Body-mass index and symptoms of gastroesophageal reflux in women. N Engl J Med. 2006; 354(22):2340-8. PMC: 2782772. DOI: 10.1056/NEJMoa054391. View

2.
Broekaert D, Fischler B, Sifrim D, Janssens J, Tack J . Influence of citalopram, a selective serotonin reuptake inhibitor, on oesophageal hypersensitivity: a double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2006; 23(3):365-70. DOI: 10.1111/j.1365-2036.2006.02772.x. View

3.
Thrift A, Kramer J, Qureshi Z, Richardson P, El-Serag H . Age at onset of GERD symptoms predicts risk of Barrett's esophagus. Am J Gastroenterol. 2013; 108(6):915-22. PMC: 3972036. DOI: 10.1038/ajg.2013.72. View

4.
Duggan C, Onstad L, Hardikar S, Blount P, Reid B, Vaughan T . Association between markers of obesity and progression from Barrett's esophagus to esophageal adenocarcinoma. Clin Gastroenterol Hepatol. 2013; 11(8):934-43. PMC: 3722274. DOI: 10.1016/j.cgh.2013.02.017. View

5.
Mittal R, ROCHESTER D, McCallum R . Electrical and mechanical activity in the human lower esophageal sphincter during diaphragmatic contraction. J Clin Invest. 1988; 81(4):1182-9. PMC: 329647. DOI: 10.1172/JCI113433. View